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Abstract
Background: Copeptin, the C-terminal part of the argi-
nine vasopressin (AVP) precursor peptide, is secreted in 
response to stress and correlates with adverse clinical 
outcomes in the acute-care hospital setting. There are no 
comprehensive data regarding its prognostic value in the 
community. We evaluated associations of copeptin levels 
with 10-year mortality in patients visiting their general 
practitioner (GP) for a respiratory infection included in a 
previous trial.
Methods: This is a post hoc analysis including data from 
359 patients included in the PARTI trial. Copeptin was 
measured in batch-analysis on admission and after 7 days. 
We calculated Cox regression models and area under the 
receiver operating characteristic curve (AUC) to assess 
an association of copeptin with mortality and adverse 
outcome. Follow-up data were collected by GP, patient 
and relative tracing through phone interviews 10  years 
after trial inclusion.
Results: After a median follow-up of 10.0 years, mortal-
ity was 9.8%. Median admission copeptin levels (pmol/L) 
were significantly elevated in non-survivors compared to 
survivors (13.8, IQR 5.9–27.8; vs. 6.3 IQR 4.1–11.5; p < 0.001). 
Admission copeptin levels were associated with 10-year 
all-cause mortality [age-adjusted hazard ratio 1.7 (95% CI, 
1.2–2.5); p < 0.001, AUC 0.68]. Results were similar for dis-
charge copeptin levels. Copeptin also predicted adverse 
outcomes defined as death, pulmonary embolism and 
major adverse cardiac and cerebrovascular events.
Conclusions: In a sample of community-dwelling patients 
visiting their GP for a respiratory infection, copeptin levels 
were associated with 10-year all-cause mortality. In con-
junction with traditional risk factors, this marker may help 
to better direct preventive measures in this population.
Keywords: biomarker; copeptin; primary care; respiratory 
tract infection; 10-year mortality.
Introduction
In primary care, detection of patients at increased risk 
of death and adverse clinical outcome is crucial to target 
intensified interventions for these high-risk individu-
als that may improve survival. Risk scores, such as the 
Framingham score, are well established and help to direct 
cardiovascular risk management, for instance, use of 
statin therapy. In addition to clinical parameters, novel 
inflammatory blood biomarkers have been proposed to 
improve prognostication [1–4]. However, as yet most bio-
marker research has looked at the acute care in a hospi-
tal setting, and the potential for primary care patients is 
incompletely understood [5, 4].
Among novel markers, copeptin, an osmo-dependent 
stress and inflammatory biomarker, has generated much 
interest [6, 7]. Copeptin, a 39-aminoacid glycopeptide, 
is the C-terminal part of the arginine vasopressin (AVP) 
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precursor peptide and is produced in the hypothalamus 
[8]. Copeptin serves as a sensitive surrogate marker for AVP 
production and parallels AVP plasma osmolality changes 
[9]. A drop in blood pressure or a change in osmotic pres-
sure induces AVP release. Further, AVP itself plays an 
important part in the endocrine stress response, acting 
as a potent synergistic factor of corticotropin-releasing 
hormone and is, therefore, a hypothalamic stimulator of 
the hypothalamo-pituitary-adrenal axis [10–14].
Several studies have reported a strong association 
of copeptin with long-term mortality mainly in hospital 
settings [15]. These studies include patients with sepsis 
[16, 17], pneumonia and lower respiratory tract infections 
[16, 18, 19], stroke [20, 21], acute myocardial infarction and 
congestive heart failure [22–25], as well as diabetes type 2 
[26], metabolic syndrome [27] and diabetes insipidus [28]. 
Also in primary care, copeptin was found to predict risk in 
patients with heart failure [29, 30], but there is no compre-
hensive data assessing the usefulness of serum copeptin 
levels as a general “risk marker” in a patient sample from 
primary care contacting general practitioners (GPs) due to 
acute respiratory tract infections (ARTIs).
Herein, we evaluated the ability of copeptin to predict 
mortality and adverse clinical outcomes in community-
dwelling patients visiting their GP for a respiratory infec-
tion followed over a 10-year-time period.
Materials and methods
Study design
This is a post hoc analysis of prognostic markers for death sam-
pled 10 years ago in the context of a primary care intervention trial 
[31]. The initial cohort included 458 adult patients with an ARTI, of 
which 359 (78.5%) could be contacted to assess long-term outcomes 
between April and August 2015.
The initial PARTI trial (“Procalcitonin-Guided Antibiotic Use vs. 
a Standard Approach for Acute Respiratory Tract Infections in Pri-
mary Care”) was a randomised, open, multicentre, non-inferiority 
trial [31]. A study protocol was published beforehand [32]. In brief, 
adult patients with an ARTI, and in their GP’s opinion in need of 
antibiotics, were randomised to either a procalcitonin (PCT)-guided 
approach or a standard approach of antibiotic therapy from Decem-
ber 13, 2004 until April 30, 2006. For the PCT-guided therapy, the use 
of antibiotics was more or less strongly discouraged based on defined 
PCT cut-off ranges [33]. The standard approach followed evidence-
based guidelines for the use of antibiotics. The aim of the trial was to 
prove the safety and efficacy of using PCT levels to guide antibiotic 
therapy.
The PARTI study protocol, as well as the present follow-up-
trial, was approved by the local Ethics Committee of Basel (EKBB), 
and all procedures conformed to the Declaration of Helsinki. Written 
informed consent, including authorisation for secondary analyses, 
was obtained from all participating physicians and patients on the 
day of randomisation.
The initial PARTI trial is registered: isrctn.org; Identifier: 
ISRCTN73182671.
Data collection and endpoints
For the current analysis, we performed follow-up interviews with 
all GPs, patients and/or relatives based on their availability. We 
assessed outcomes using systematic questionnaires. There was no 
blinded assessment for outcomes.
Also, the register of death of the cantons Basel-Stadt and Basel-
Land was consulted if no information about vital status was avail-
able. From a total of 458 patients with an ARTI included in the initial 
trial, 359 patients were included in the follow-up study (276 patients 
were assessed through 40 primary care physicians, 73 patients were 
contacted by phone calls, nine patients were detected via the regis-
ters of death and one patient died during the 28-day follow-up period 
of the initial trial).
The primary outcome was 10-year all-cause mortality. Second-
ary outcomes were adverse outcome events including death, pulmo-
nary embolism and major adverse cardiac or cerebrovascular events 
(MACCE), which includes cardiac infarction, cardiac arrest, stroke 
and transient ischemic attack. We also looked separately at MACCE 
and stroke as secondary outcomes.
Analysis of blood biomarkers
Blood samples were collected in the primary care centre from each 
patient on the day of randomisation, as well as after 7 days, and 
sent by courier to the central Laboratory of the University Hospital 
Basel for measurement of PCT. Leftover blood samples were frozen 
and stored at –80 °C for the later measurement of prognostic mark-
ers. Copeptin serum values were determined using a novel sandwich 
immunoluminometric assay (B.R.A.H.M.S GmbH, Hennigsdorf, 
Germany) with intra- and inter-assay coefficients of variation of up 
to 20% using an automated immunofluorescent assay (Kryptor©, 
B.R.A.H.M.S GmbH, Hennigsdorf, Germany) [34, 35].
Statistical analyses
Categorical variables are expressed as percentages (numbers) and 
continuous variables as medians [interquartile ranges (IQRs)], unless 
stated otherwise. If applicable, 95% confidence intervals (CIs) are 
presented. The χ2 (Wald) test is used for frequency comparisons, the 
non-parametric (Mann-Whitney-U) test for two-sample comparisons.
We analysed the associations of copeptin with primary and sec-
ondary outcomes using univariable and multivariable Cox regression 
analyses adjusting for age (bivariable model) as well as age, gender, 
randomisation arm, antibiotic use initially, smoking history, comor-
bidities and type of infection (fully adjusted model). We report hazard 
ratios (HRs) and 95% CIs as a measure of association and C-Statistics 
[area under the curve (AUC)] as a measure of discrimination. As the 
distribution of raw biomarker data was skewed, we used a natural 
logarithm (base e) transformation. Thereafter, the distribution of the 
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biomarker data approximated a normal distribution. The HR thereby 
corresponds to a nearly one-fourth-unit increase in the explanatory 
variable and to a 2.72-fold increase in log-transformed biomarker lev-
els. Further, for illustration, we present Kaplan-Meier survival esti-
mates of long-term survival by quartiles of copeptin levels.
Statistical analyses were performed using STATA 12.1 (STATA 
Corp, College Station, TX, USA). A p-value < 0.05 indicated statistical 
significance.
Results
Patient characteristics
Baseline characteristics of the entire cohort (n = 359) 
as well as stratified by the primary endpoint (10-year 
vital status) and the main secondary endpoint (adverse 
outcome) are shown in Table 1. The overall median age 
was 45.0 and 38.2% (137) of the patients were male. There 
were differences in age, comorbidities (arterial hyperten-
sion, chronic obstructive pulmonary disease), initial clini-
cal classification for ARTI (lower vs. upper) at the day of 
randomisation and nicotine consumption according to 
the survival status.
However, there was no significant difference found 
between the traceable patients (n = 359) and the popula-
tion that was lost to follow-up (n = 99) (see Supplemental 
Data, Table S1).
Primary outcome: 10-year all-cause mortality
A total of 35 of the 359 patients (9.8%) died during the 10.0 
(IQR 9.5–10.3) years of follow-up. Median baseline copep-
tin blood levels (pmol/L) were significantly higher in non-
survivors compared to survivors (13.8, IQR 5.9–27.8; vs. 6.3, 
IQR 4.1–11.5; p < 0.001). Similarly, biomarker results at day 
7 also showed significant differences between survivors 
and non-survivors (11.2, IQR 3.2–21.2; vs. 4.5, IQR 2.9–7.4; 
p < 0.001).
A strong association of copeptin with an outcome was 
also found in Cox regression analysis as summarised for 
admission blood levels in Table 2 and for follow-up blood 
levels in Table 3. The age-adjusted HR of copeptin for 
prediction of mortality was 1.7 (95% CI 1.2–2.5, p = 0.005) 
and 2.5 (95% CI 1.6–4.0, p < 0.001) at day 7. We also found 
fair discrimination with AUCs of 0.68 (95% CI 0.6–0.8) at 
baseline and 0.71 (95% CI 0.6–0.8) at day 7 (Figure 1). The 
results also remained robust in a fully adjusted model 
including age, gender, randomisation arm, antibiotic 
use initially, smoking history, comorbidities and type of 
infection.
To further illustrate these associations, we generated 
Kaplan-Meier curves (Figure 2 and Supplemental Data, 
Figure S1), with patients stratified based on copeptin 
blood level quartiles. Mortality was significantly increased 
in patients in the highest copeptin quartile compared to 
quartiles 1–3.
We also performed several exploratory subgroup anal-
yses as presented in Tables 2 and 3. Although discrimina-
tion was highest for patients  < 60 years of age (AUC 0.77) 
and for females (AUC 0.69), there was no evidence of signif-
icant effect modification (Figure 1). We also calculated sen-
sitivity and specificity for different copeptin cut-off levels 
for all-cause mortality prediction. Sensitivity was 91.4% at 
a 3 pmol/L cut-off with however a low specificity of 13.6%. 
Conversely, specificity was 80.9% at the 15 pmol/L cut-off 
with a sensitivity of 42.9%. Detailed results including posi-
tive (PPV) and negative predictive values (NPV) are pre-
sented (see Supplemental Data, Table S2).
Secondary outcomes: 10-year incidence 
of adverse outcome events
A total of 52 patients (14.5%) reported to have experienced 
an adverse outcome event defined as death, pulmonary 
embolism or major adverse cardiac and cerebrovascular 
events. Copeptin blood levels were significantly elevated 
in these patients at baseline and at day 7 compared to 
the patients not having an event. Again, Cox regression 
models found significant associations between both 
initial and day 7 copeptin levels and adverse outcome, 
with fair discrimination (Tables 2 and 3).
Kaplan-Meier curves (Figure 2), with patients strati-
fied based on copeptin quartiles, again found higher event 
rates in patients in the highest copeptin quartile.
We also explored associations of copeptin with dif-
ferent components of adverse outcome, namely MACCE 
(n = 19) and stroke (n = 8) (see Supplemental Data, 
Tables  S3 and S4). Although copeptin was increased in 
patients reaching these endpoints, statistically significant 
associations were not found in regression models.
Discussion
The key finding of this first prospective, observational 
10-year follow-up study including community-dwelling 
patients visiting their GP for a respiratory infection is that 
copeptin measured during the index visit and 7 days later 
was a predictor for 10-year all-cause mortality and inci-
dence of adverse outcome. Thereby these data expand 
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Table 2: Association between copeptin blood levels at baseline and outcomes: 10-year all-cause mortality and 10-year incidence of adverse 
outcome.
  10-Year all-cause mortality   10-Year incidence of adverse outcome
Overall   n = 35   n = 52
 Unadjusted HR   2.2 (95% CI 1.5–3.4), p < 0.001   2.0 (95% CI 1.4–2.8), p < 0.001
 Adjusted for age HR   1.7 (95% CI 1.2–2.5), p = 0.005   1.6 (95% CI 1.2–2.2), p = 0.003
 Fully adjusted model HR   1.7 (95% CI 1.1–2.6), p = 0.027   1.6 (95% CI 1.1–2.2), p = 0.021
 AUC   0.68 (95% CI 0.57–0.78)   0.66 (95% CI 0.58–0.75)
   
Specific subgroups
 Gender   pa = 0.781   pa = 0.554
  Male   n = 21   n = 32
   Unadjusted HR   1.8 (95% CI 1.1–3.2), p = 0.031   1.6 (95% CI 1.0–2.5), p = 0.032
   Adjusted for age HR   1.3 (95% CI 0.8–2.4), p = 0.294   1.2 (95% CI 0.8–2.0), p = 0.350
   AUC   0.63 (95% CI 0.49–0.78)   0.62 (95% CI 0.50–0.73)
   
  Female   n = 14   n = 20
   Unadjusted HR   2.5 (95% CI 1.4– 4.5), p = 0.003   2.2 (95% CI 1.3–3.7), p = 0.003
   Adjusted for age HR   1.9 (95% CI 1.1–3.2), p = 0.030   1.7 (95% CI 1.1–2.8), p = 0.028
   AUC   0.69 (95% CI 0.52–0.87)   0.66 (95% CI 0.52–0.80)
   
Nicotine abuse   pa = 0.988   pa = 0.925
 Smoker   n = 16   n = 21
  Unadjusted HR   2.1 (95% CI 1.1–3.9), p = 0.020   2.0 (95% CI 1.1–3.5), p = 0.018
  Adjusted for age HR   1.8 (95% CI 1.0–3.1), p = 0.046   2.0 (95% CI 1.1–3.4), p = 0.015
  AUC   0.67 (95% CI 0.50–0.83)   0.65 (95% CI 0.51–0.79)
   
 Non-smoker   n = 19   n = 31
  Unadjusted HR   2.4 (95% CI 1.4– 4.2), p = 0.001   2.1 (95% CI 1.4–3.2), p = 0.001
  Adjusted for age HR   1.7 (95% CI 1.0–2.9), p = 0.038   1.5 (95% CI 1.0–2.3), p = 0.059
  AUC   0.70 (95% CI 0.55–0.84)   0.68 (95% CI 0.56–0.79)
   
Age   pa = 0.683   pa = 0.596
 >60   n = 32   n = 43
  Unadjusted HR   1.6 (95% CI 1.1–2.4), p = 0.019   1.6 (95% CI 1.1–2.2), p = 0.011
  Adjusted for gender HR  1.4 (95% CI 0.9–2.2), p = 0.089   1.4 (95% CI 1.0–2.0), p = 0.070
  AUC   0.63 (95% CI 0.50–0.76)   0.64 (95% CI 0.52–0.75)
   
  ≤ 60   n = 3   n = 9
  Unadjusted HR   3.2 (95% CI 0.8–13.2), p = 0.113   1.6 (95% CI 0.7–3.9), p = 0.252
  Adjusted for gender HR  2.9 (95% CI 0.7–12.6), p = 0.155   1.3 (95% CI 0.6–3.1), p = 0.539
  AUC   0.77 (95% CI 0.50–1.0)   0.63 (95% CI 0.44–0.81)
ap-Value for subgroup interaction. Data for univariable and multivariable analyses are given as HR (95% CI) and p-value. Data regarding 
prognostic analysis are given as AUC (95% CI). A higher AUC reflects greater accuracy: 0.5, the null value, indicates coin-toss accuracy, while 
1.0, the maximum value indicates 100% accuracy. p-Values in bold type are statistically significant at < 0.05. The univariable model includes: 
the natural logarithmic value of admission copeptin blood concentrations. The bivariable model includes: the natural logarithmic value of 
admission copeptin blood concentrations and patient age or gender, depending on the subgroup. The fully adjusted model includes: the 
natural logarithmic value of admission copeptin blood concentrations and patient age, gender, randomisation arm, antibiotic use initially, 
smoking history, comorbidities and type of infection.
data from the hospital setting to primary care and suggest 
that this marker may be useful in the risk assessment of 
this patient population.
Several studies have reported associations of copeptin 
levels with adverse outcomes, namely mortality [15–30].
It has been speculated that through its implication in 
the stress response, copeptin may help to detect higher 
severity of somatic disease. In patients with chest pain, 
for example, low copeptin levels can exclude myocardial 
infarction with high NPV [36]. Similarly, in patients with 
respiratory infection and low copeptin levels, adverse 
clinical outcomes are highly unlikely. In our study, a 
copeptin level of   ≤  3 pmol/L had an NPV of 93.6% for mor-
tality and thus makes this endpoint highly unlikely. Con-
versely, in patients with copeptin  ≥ 15 pmol/L mortality is 
much more likely as evidenced by a PPV of 19.5%.
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Table 3: Association between copeptin blood levels at day 7 follow-up and outcomes: 10-year all-cause mortality and 10-year incidence of 
adverse outcome.
  10-Year all-cause mortality   10-Year incidence of adverse outcome
Overall   n = 35   n = 52
 Unadjusted HR   3.3 (95% CI 2–5.4), p < 0.001   2.4 (95% CI 1.6–3.5), p < 0.001
 Adjusted for age HR   2.5 (95% CI 1.6–4.0), p < 0.001   1.9 (95% CI 1.3–2.7), p = 0.001
 Fully adjusted model HR   2.5 (95% CI 1.5–4.2), p = 0.001   1.8 (95% CI 1.2–2.6), p = 0.006
 AUC   0.71 (95% CI 0.59–0.83)   0.66 (95% CI 0.56–0.76)
Specific subgroups
 Gender   pa = 0.65   pa = 0.951
  Male   n = 21   n = 32
   Unadjusted HR   3.5 (95% CI 1.9–6.8), p < 0.001   2.3 (95% CI 1.4–3.8), p = 0.001
   Adjusted for age HR   2.6 (95% CI 1.4–4.9), p = 0.004   1.7 (95% CI 1.0–2.8), p = 0.033
   AUC   0.72 (95% CI 0.55–0.89)   0.65 (95% CI 0.52–0.78)
  Female   n = 14   n = 20
   Unadjusted HR   2.6 (95% CI 1.3–5.6), p = 0.011   2.1 (95% CI 1.1–4.0), p = 0.02
   Adjusted for age HR   2.1 (95% CI 1.0–4.2), p = 0.039   1.7 (95% CI 1–3.2), p = 0.067
   AUC   0.67 (95% CI 0.49–0.85)   0.64 (95% CI 0.48–0.79)
Nicotine abuse   pa = 0.552   pa = 0.541
 Smoker   n = 16   n = 21
  Unadjusted HR   3.0 (95% CI 1.5–6.3), p = 0.003   2.4 (95% CI 1.3–4.4), p = 0.007
  Adjusted for age HR   2.9 (95% CI 1.5–5.6), p = 0.002   2.7 (95% CI 1.5–5.1), p = 0.001
  AUC   0.67 (95% CI 0.47–0.87)   0.62 (95% CI 0.45–0.78)
 Non-smoker   n = 19   n = 31
  Unadjusted HR   3.6 (95% CI 1.9–6.8), p < 0.001   2.4 (95% CI 1.5–4.1), p = 0.001
  Adjusted for age HR   2.4 (95% CI 1.2–4.6), p = 0.011   1.6 (95% CI 1.0–2.6), p = 0.073
  AUC   0.74 (95% CI 0.58–0.89)   0.69 (95% CI 0.57–0.80)
Age   pa = 0.894   pa = 0.744
 >60   n = 32   n = 43
  Unadjusted HR   2.4 (95% CI 1.4–3.9), p = 0.001   1.8 (95% CI 1.2–2.8), p = 0.005
  Adjusted for gender HR  2.1 (95% CI 1.3–3.5), p = 0.003   1.6 (95% CI 1.1–2.5), p = 0.023
  AUC   0.68 (95% CI 0.53–0.82)   0.63 (95% CI 0.51–0.76)
  ≤ 60   n = 3   n = 9
  Unadjusted HR   5.2 (95% CI 1.0–26.2), p = 0.046   2.3 (95% CI 0.9–6.0), p = 0.088
  Adjusted for gender HR  4.8 (95% CI 0.9–24.4), p = 0.058   2.0 (95% CI 0.8–5.2), p = 0.168
  AUC   0.82 (95% CI 0.56–1.0)   0.66 (95% CI 0.43–0.88)
ap-Value for subgroup interaction. Data for univariable and multivariable analyses are given as HR (95% CI) and p-value. Data regarding 
prognostic analysis are given as AUC (95% CI). A higher AUC reflects greater accuracy: 0.5, the null value, indicates coin-tossaccuracy, 
while 1.0, the maximum value indicates 100% accuracy. p-Values in bold type are statistically significant at  < 0.05. The univariable model 
includes: the natural logarithmic value of day 7 follow-up copeptin blood concentrations. The bivariable model includes: the natural loga-
rithmic value of day 7 follow-up copeptin blood concentrations and patient age or gender, depending on the subgroup. The fully adjusted 
model includes: the natural logarithmic value of day 7 follow-up copeptin blood concentrations and patient age, gender, randomisation arm, 
antibiotic use initially, smoking history, comorbidities and type of infection.
Copeptin also showed statistically significant asso-
ciations with the incidence of adverse outcomes defined 
as death, pulmonary embolism or major adverse cardiac 
and cerebrovascular events. However, associations were 
not found for stroke and MACCE themselves, but there are 
possible explanations. First, our study had only a limited 
number of patients suffering events, owing to the gener-
ally healthy patient population under study with a low 
burden of comorbidities. Further, our results indicate that 
copeptin, as a marker of non-specific stress response, is 
better at tracking the risk of death than predicting the 
incidence of cardio- and/or cerebrovascular events. For 
example, Sun et al. found in a meta-analysis with 14,395 
cardio-cerebrovascular patients that copeptin was asso-
ciated with all-cause mortality [37]. Therefore, copeptin 
seems to be more accurate in identifying the patients at 
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Figure 1: Forest plot of copeptins prognostic accuracy in predicting 10-year all-cause mortality in different patients subgroups.
Figure 2: 10-year Kaplan-Meier survival and without adverse outcome curve according to baseline copeptin blood concentration.
Plots showing the association between endpoint and copeptin quartiles, 4th quartile vs. 1st–3rd quartiles and between 1st, 2nd, 3rd and 
4th quartile.
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risk of death, rather than in predicting specific medical 
diagnosis in a long-term follow-up of generally healthy 
outpatients. Nonetheless, we are aware that there are 
studies showing an association of copeptin levels with 
MACCE and stroke in subpopulations such as patients 
with type 2 diabetes [27, 38] or undergoing haemodialysis 
[39], and that copeptin seems to be a valid biomarker to 
potentially rule out acute myocardial infarction, in the 
acute phase of the disease [36, 40–43].
In our study population, copeptin blood levels were 
not significantly influenced by age, gender or smoking 
status, confirmed statistically in the interaction analysis. 
Former studies demonstrated similar results with no sig-
nificant correlation of copeptin with gender [44] or age 
[34]. Bosselmann et  al. showed that copeptin and other 
cardiovascular biomarkers are closely associated with 
renal function in heart failure. Still, the marker was useful 
for risk stratification independently of renal function [45]. 
Also, Choi et al. found a standardised mean difference by 
study region with significant differences in copeptin blood 
levels, but a positive consistent association of copeptin 
with poor prognosis [46].
Interestingly, we had access to copeptin levels on 
admission to the GP’s office, i.e. in patients suffering 
from ARTI and 7 days later when the infection may have 
been cured. Our results suggest that copeptin blood levels 
taken on a 7-day follow-up have a slightly stronger asso-
ciation with outcome compared to admission results for 
mortality and adverse clinical outcome prediction. In con-
trast, a meta-analysis of Choi et al. in a different setting 
showed that early measurement of plasma copeptin in 
the patients with acute stroke provides better prognostic 
information about the functional outcome and mortality 
[46]. Because differences in our study sample were small, 
further research is needed to define the optimal usage of 
this marker in the GP setting.
As mentioned before, measurements of copeptin 
levels have been demonstrated to be useful in a variety of 
clinical scenarios. The potential benefit of copeptin com-
pared to other biomarkers is due to its central role as a 
marker for a key hormone in the body. It is not restricted 
to a single organ system and is triggered by many disease 
processes. This lack of specificity with regard to the 
underlying diagnosis may be an advantage as a more 
generalisable marker for severe disturbances in patient 
physiology [14].
Katan et  al. have shown that copeptin levels mirror 
different levels of stress more accurately than cortisol 
[28]. Cortisol measurements are limited by, for example, 
cross-reactivity with other steroids [47]; its concentration 
varies with the amount of hormone-binding proteins, 
underlies a circadian rhythm [48] and changes with food 
intake [49].
The main strengths of this study include the participa-
tion of multiple GP practices, the long follow-up period of 
10 years and the community sample of patients with ARTI 
of different severity representative for patients mainly 
treated in primary care.
However, we are aware of several limitations. Firstly, 
the incomplete baseline risk assessment in the original 
cohort, in particular, missing certain blood parameters 
such as lipid values or blood pressure, does not allow 
us to investigate whether copeptin would improve state-
of-the-art risk scores (e.g. Framingham). Secondly, while 
the register of deaths could confirm the survival status of 
the patients, no information was available on the cause of 
death. There is also the possibility that the GPs have not 
seen their patients on a regular basis, or that the relatives 
did not remember their medical information. Therefore, 
we limited our analysis to all-cause mortality rather than 
to cause-specific mortality. Thirdly, we lack in comprehen-
sive measurement of confounders. Thus, our results are 
biased by confounding we cannot control for. Finally, our 
sample was small in size with a follow-up rate of 78.5% 
and we observed only few events. We were therefore not 
able to look into short-term adverse outcomes in this study 
and a larger trial is needed.
Conclusions
In a sample of community-dwelling patients visiting their 
GP for a respiratory infection, copeptin was associated 
with a 10-year all-cause mortality. In conjunction with tra-
ditional risk factors, this marker may help to better direct 
preventive measures in this population. Still, further evi-
dence must determine the role of copeptin in primary care 
as a marker of risk stratification, by evaluating whether 
preventive interventions help to reduce mortality risk in 
this population.
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